Myozyme

Myozyme is a biotechnology-derived enzyme product developed for individuals affected by Pompe disease, a rare inherited metabolic condition caused by deficiency of the enzyme acid alpha-glucosidase. This deficiency leads to the accumulation of glycogen in muscle tissues, resulting in progressive muscle weakness, respiratory difficulties, and reduced physical function. Alglucosidase alfa, the active component in Myozyme, is a recombinant form of the human enzyme designed to replace the missing or insufficient natural enzyme in the body.
The therapy works by breaking down excess glycogen stored in cells, particularly in skeletal and cardiac muscle tissue. By supporting normal glycogen metabolism, it helps improve muscle performance, mobility, and breathing capacity, which are commonly affected in Pompe disease. Long-term use has been associated with better survival outcomes and improved quality of life, especially when started early in disease progression.
Myozyme is produced using advanced genetic engineering and cell culture technology, ensuring a highly purified and biologically active enzyme. It is part of enzyme replacement strategies that aim to correct the underlying biochemical cause rather than just managing symptoms. Research and clinical experience have shown that consistent therapy can slow disease progression and preserve muscle structure and function.
Overall, alglucosidase alfa represents a major advancement in rare disease care, offering targeted biological support for a complex genetic disorder. Its development has transformed Pompe disease management by addressing the root enzymatic deficiency and providing patients with a scientifically driven, disease-specific therapeutic option.